ZSQR — Coeptis Therapeutics Holdings Share Price
0.000.00%
Last trade - 00:00- $667.58m
- $661.99m
- $1.36m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 49.22 | ||
| Price to Tang. Book | 50.57 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 489.77 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -89.56% | ||
| Return on Equity | -142.32% | ||
| Operating Margin | -945.27% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 1.36 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company. The Company is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its segments are Biotechnology and Technology. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- December 31st, 2025
- Incorporated
- October 27th, 2022
- Public Since
- December 17th, 2020
- No. of Shareholders
- 128
- No. of Employees
- 4
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 51,431,493
- Address
- 105 Bradford Road, Suite 420, WEXFORD, 15090
- Web
- https://coeptistx.com/
- Phone
- +1 3026365400
- Auditors
- Turner, Stone & Company
Upcoming Events for ZSQR
Q2 2026 Coeptis Therapeutics Holdings Inc Earnings Release
Similar to ZSQR
Abivax SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Actuate Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
Adlai Nortye
NASDAQ Global Market
FAQ
What is the Coeptis Therapeutics Holdings share price?
As of Today at 06:18 UTC, shares in Coeptis Therapeutics Holdings are trading at . This share price information is delayed by 15 minutes.
How has the Coeptis Therapeutics Holdings share price performed this year?
Shares in Coeptis Therapeutics Holdings last closed at and the price had moved by +56.95% over the past 365 days. In terms of relative price strength the Coeptis Therapeutics Holdings share price has outperformed the S&P500 Index by +21.16% over the past year.
What are the analyst and broker recommendations for Coeptis Therapeutics Holdings?
The overall consensus recommendation for Coeptis Therapeutics Holdings is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Coeptis Therapeutics Holdings dividend yield?
Coeptis Therapeutics Holdings does not currently pay a dividend.
Does Coeptis Therapeutics Holdings pay a dividend?
Coeptis Therapeutics Holdings does not currently pay a dividend.
When does Coeptis Therapeutics Holdings next pay dividends?
Coeptis Therapeutics Holdings does not currently pay a dividend.
How do I buy Coeptis Therapeutics Holdings shares?
To buy shares in Coeptis Therapeutics Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Coeptis Therapeutics Holdings?
As of the previous close price of , shares in Coeptis Therapeutics Holdings had a market capitalisation of $667.58m.
Where are Coeptis Therapeutics Holdings shares listed?
Here are the trading details for Coeptis Therapeutics Holdings:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ZSQR
What kind of share is Coeptis Therapeutics Holdings?
Based on an overall assessment of its quality, value and momentum Coeptis Therapeutics Holdings is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Coeptis Therapeutics Holdings share price forecast for 2026?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Coeptis Therapeutics Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Coeptis Therapeutics Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -11.84%.
As of the last closing price of , shares in Coeptis Therapeutics Holdings were trading -5.77% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Coeptis Therapeutics Holdings PE Ratio?
The Coeptis Therapeutics Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at .
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Coeptis Therapeutics Holdings?
We do not have data on Coeptis Therapeutics Holdings' directors